You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 161 No. 20, November 12, 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (49)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Genetic Disorders
 •Genetics, Other
 •Musculoskeletal Syndromes (Chronic Fatigue, Gulf War)
 •Congenital Heart Defects
 •Dermatology
 •Connective Tissue Diseases
 •Alert me on articles by topic


Genotype and Phenotype Analysis of 171 Patients Referred for Molecular Study of the Fibrillin-1 Gene FBN1 Because of Suspected Marfan Syndrome

Bart Loeys, MD; Lieve Nuytinck, PhD; Isabelle Delvaux; Sylvia De Bie, MS; Anne De Paepe, MD, PhD

Arch Intern Med. 2001;161:2447-2454.

Background  Marfan syndrome (MFS) is an underrecognized heritable connective tissue disorder resulting from mutations in the gene for fibrillin-1 (FBN1). Affected patients are at risk for aortic dissection and/or severe ocular and orthopedic problems. The diagnosis is primarily based on a set of well-defined clinical criteria (Ghent nosology). The age-related nature of some clinical manifestations and variable phenotypic expression may hinder the diagnosis, particularly in children. Molecular analysis may be helpful to identify at-risk individuals early and start prophylactic medical treatment. FBN1 mutations have also been reported in patients with Marfan-related conditions, but it is unknown what proportion of all FBN1 mutation carriers they represent.

Methods  We reviewed the clinical and molecular data of 171 consecutive patients referred for FBN1 analysis because either MFS was diagnosed or they had signs suggestive of MFS. We compared the incidence of mutations in patients who fulfilled the clinical diagnostic criteria for MFS with those who did not.

Results  Diagnostic criteria for MFS were fulfilled in 94 patients, 62 (66%) of whom had an FBN1 mutation. A significantly higher incidence of ectopia lentis was found in the patients with MFS with an FBN1 mutation vs those without (P=.04). Among the 77 patients who did not meet the criteria, an FBN1 mutation was found in 9 patients (12%). No correlation was found between the severity of the phenotype and the position and nature of the FBN1 mutation.

Conclusions  This study showed a significant difference in the number of FBN1 mutations between patients fulfilling and those not fulfilling the diagnostic criteria for MFS, which seems to be a good predictor of the presence of an FBN1 mutation. A comprehensive clinical evaluation is mandatory before establishing a definitive diagnosis. An FBN1 mutation analysis is helpful to identify individuals at high risk for MFS who need careful follow-up, particularly in families displaying phenotypic variability and in children.


From the Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium.


RELATED ARTICLES

Genetic Testing and Medical Decision Making
Valerie F. Reyna, Farrell J. Lloyd, and Patrick Whalen
Arch Intern Med. 2001;161(20):2406-2408.
EXTRACT | FULL TEXT  

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(20):2511-2512.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
Faivre et al.
J. Med. Genet. 2008;45:384-390.
ABSTRACT | FULL TEXT  

The molecular genetics of Marfan syndrome and related disorders
Robinson et al.
J. Med. Genet. 2006;43:769-787.
ABSTRACT | FULL TEXT  

Immunohistochemical evaluation of conjunctival fibrillin-1 in Marfan syndrome.
Ganesh et al.
Arch Ophthalmol 2006;124:205-209.
ABSTRACT | FULL TEXT  

Diagnostic power of aortic elastic properties in young patients with Marfan syndrome
Baumgartner et al.
J. Thorac. Cardiovasc. Surg. 2005;129:730-739.
ABSTRACT | FULL TEXT  

Treatment of Aortic Disease in Patients With Marfan Syndrome
Milewicz et al.
Circulation 2005;111:e150-e157.
FULL TEXT  

Pigmented Paravenous Chorioretinal Atrophy Is Associated with a Mutation within the Crumbs Homolog 1 (CRB1) Gene
McKay et al.
IOVS 2005;46:322-328.
ABSTRACT | FULL TEXT  

Should the transverse aortic arch be replaced simultaneously with aortic root replacement for annuloaortic ectasia in Marfan syndrome?
Tagusari et al.
J. Thorac. Cardiovasc. Surg. 2004;127:1373-1380.
ABSTRACT | FULL TEXT  

Muscle fibrillin deficiency in Marfan's syndrome myopathy
Behan et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:633-638.
ABSTRACT | FULL TEXT  

Solution Structure and Dynamics of a Calcium Binding Epidermal Growth Factor-like Domain Pair from the Neonatal Region of Human Fibrillin-1
Smallridge et al.
J. Biol. Chem. 2003;278:12199-12206.
ABSTRACT | FULL TEXT  

Identification of FBN1 gene mutations in patients with ectopia lentis and marfanoid habitus
Comeglio et al.
Br. J. Ophthalmol. 2002;86:1359-1362.
ABSTRACT | FULL TEXT  

Management of Marfan syndrome
Dean
Heart 2002;88:97-103.
FULL TEXT  

Genetic Testing and Medical Decision Making
Reyna et al.
Arch Intern Med 2001;161:2406-2408.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.